NASDAQ:NEO NeoGenomics (NEO) Stock Forecast, Price & News $12.42 +0.11 (+0.89%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$12.31▼$12.6350-Day Range$12.15▼$17.5452-Week Range$6.00▼$20.54Volume501,944 shsAverage Volume970,827 shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice Target$19.18 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media NeoGenomics MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside54.4% Upside$19.18 Price TargetShort InterestBearish4.67% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.00Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.44) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector415th out of 976 stocksTesting Laboratories Industry1st out of 1 stocks 4.4 Analyst's Opinion Consensus RatingNeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.18, NeoGenomics has a forecasted upside of 54.4% from its current price of $12.42.Amount of Analyst CoverageNeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.67% of the outstanding shares of NeoGenomics have been sold short.Short Interest Ratio / Days to CoverNeoGenomics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in NeoGenomics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoGenomics does not currently pay a dividend.Dividend GrowthNeoGenomics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEO. Previous Next 2.8 News and Social Media Coverage News SentimentNeoGenomics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NeoGenomics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NeoGenomics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NeoGenomics is held by insiders.Percentage Held by Institutions91.36% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NeoGenomics are expected to grow in the coming year, from ($0.44) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NeoGenomics is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeoGenomics is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoGenomics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NeoGenomics (NASDAQ:NEO) StockNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.Read More NEO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEO Stock News HeadlinesSeptember 27, 2023 | finance.yahoo.comChroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of DirectorsSeptember 26, 2023 | thestreet.comNeoGenomics Deal With GE's Clarient 6 Months Later: Boom or Bust?September 28, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.September 22, 2023 | msn.comOne year after Hurricane Ian: 10 'truths' about historic storm's impact on Southwest FloridaAugust 21, 2023 | msn.comStephens & Co. Upgrades Neogenomics (NEO)August 21, 2023 | markets.businessinsider.com4 Analysts Have This to Say About NeoGenomicsAugust 11, 2023 | msn.comBenchmark Maintains Neogenomics (NEO) Buy RecommendationAugust 10, 2023 | finance.yahoo.comNeoGenomics Inc (NG9.BE)September 28, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 9, 2023 | msn.comFort Myers-based NeoGenomics grew revenues in Q2, and narrowed its lossesAugust 9, 2023 | msn.comNeoGenomics: Asset Growth Yet To Scale Gross Profitability, Reiterate HoldAugust 8, 2023 | msn.comNeoGenomics Raises Annual Guidance After Solid Q2 Earnings BeatAugust 8, 2023 | finance.yahoo.comNeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesAugust 8, 2023 | finanznachrichten.deNeoGenomics, Inc.: NeoGenomics Reports Second Quarter 2023 ResultsAugust 8, 2023 | msn.comNeoGenomics Non-GAAP EPS of -$0.05 beats by $0.06, revenue of $146.92M beats by $9.49MAugust 8, 2023 | finance.yahoo.comNeoGenomics Reports Second Quarter 2023 ResultsAugust 8, 2023 | seekingalpha.comNeoGenomics, Inc. 2023 Q2 - Results - Earnings Call PresentationJuly 28, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on NeoGenomics (NEO)July 27, 2023 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on NeoGenomics (NEO)July 27, 2023 | finanznachrichten.deNeoGenomics, Inc.: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast CancerJuly 27, 2023 | finance.yahoo.comNeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast CancerJuly 25, 2023 | finance.yahoo.comNEO - NeoGenomics, Inc.July 18, 2023 | finance.yahoo.comNeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023June 29, 2023 | finanznachrichten.deNeoGenomics, Inc.: NeoGenomics Expands Board of Directors with Appointments of Three Independent DirectorsJune 29, 2023 | finance.yahoo.comNeoGenomics Expands Board of Directors with Appointments of Three Independent DirectorsJune 22, 2023 | marketwatch.comGene Test Service Market 2023 Business Scenario - LabCorp, Quest Diagnostics, Genomic Health, NeoGenomics, Eurofins ScientificJune 15, 2023 | finanznachrichten.deNeoGenomics, Inc.: NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial CoverageSee More Headlines Receive NEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter. Email Address NEO Company Calendar Last Earnings8/08/2023Today9/28/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Testing laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NEO CUSIPN/A CIK1077183 Webwww.neogenomics.com Phone(239) 768-0600Fax239-690-4237Employees2,100Year Founded2002Price Target and Rating Average Stock Price Forecast$19.18 High Stock Price Forecast$25.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside+54.4%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-144,250,000.00 Net Margins-20.79% Pretax Margin-22.75% Return on Equity-6.36% Return on Assets-3.64% Debt Debt-to-Equity Ratio0.56 Current Ratio6.16 Quick Ratio5.90 Sales & Book Value Annual Sales$551.62 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book1.57Miscellaneous Outstanding Shares127,552,000Free Float125,894,000Market Cap$1.58 billion OptionableOptionable Beta1.08 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Christopher Michael Smith BSc (Age 60)CEO & Director Comp: $3.52MMr. Jeffrey S. Sherman M.B.A. (Age 57)Chief Financial Officer Comp: $492.31kMr. Vishal Sikri (Age 47)Pres of Advanced Diagnostics Division Comp: $1.21MMr. Warren Stone (Age 50)Pres of Clinical Division Comp: $722.79kMs. Cynthia J. Dieter (Age 48)Chief Accounting Officer Mr. Greg SparksChief Technology OfficerMs. Kendra SweeneyVP of Investor Relations & CommunicationsMs. Alicia Olivo (Age 39)Gen. Counsel & Corp. Sec. Mr. Hutan Hashemi J.D. (Age 44)Chief Compliance Officer Dr. Derek Lyle M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsCrinetics PharmaceuticalsNASDAQ:CRNXNextGen HealthcareNASDAQ:NXGNSupernus PharmaceuticalsNASDAQ:SUPNVericelNASDAQ:VCELPacira BioSciencesNASDAQ:PCRXView All CompetitorsInstitutional OwnershipBarclays PLCBought 8,083 shares on 9/21/2023Ownership: 0.058%Virginia Retirement Systems ET ALBought 21,700 shares on 8/22/2023Ownership: 0.017%California State Teachers Retirement SystemBought 2,391 shares on 8/21/2023Ownership: 0.121%Teachers Retirement System of The State of KentuckyBought 2,210 shares on 8/21/2023Ownership: 0.031%Osaic Holdings Inc.Sold 21,505 shares on 8/21/2023Ownership: 0.020%View All Institutional Transactions NEO Stock - Frequently Asked Questions Should I buy or sell NeoGenomics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares. View NEO analyst ratings or view top-rated stocks. What is NeoGenomics' stock price forecast for 2023? 11 analysts have issued 1-year price targets for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $19.18 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for NEO or view top-rated stocks among Wall Street analysts. How have NEO shares performed in 2023? NeoGenomics' stock was trading at $9.24 at the start of the year. Since then, NEO shares have increased by 34.4% and is now trading at $12.42. View the best growth stocks for 2023 here. When is NeoGenomics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our NEO earnings forecast. How were NeoGenomics' earnings last quarter? NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, August, 8th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.06. The medical research company had revenue of $146.92 million for the quarter, compared to analysts' expectations of $138.22 million. NeoGenomics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 6.36%. What ETFs hold NeoGenomics' stock? ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY). What guidance has NeoGenomics issued on next quarter's earnings? NeoGenomics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of -$0.28--$0.23 for the period, compared to the consensus earnings per share estimate of -$0.36. The company issued revenue guidance of $565.00 million-$575.00 million, compared to the consensus revenue estimate of $562.42 million. What is Douglas M. VanOort's approval rating as NeoGenomics' CEO? 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of NeoGenomics own? Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV). What is NeoGenomics' stock symbol? NeoGenomics trades on the NASDAQ under the ticker symbol "NEO." Who are NeoGenomics' major shareholders? NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (5.17%), State Street Corp (3.86%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.05%), Schroder Investment Management Group (1.56%) and Northern Trust Corp (1.24%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello. View institutional ownership trends. How do I buy shares of NeoGenomics? Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NeoGenomics' stock price today? One share of NEO stock can currently be purchased for approximately $12.42. How much money does NeoGenomics make? NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.58 billion and generates $551.62 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis. How many employees does NeoGenomics have? The company employs 2,100 workers across the globe. Does NeoGenomics have any subsidiaries? The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.Read More How can I contact NeoGenomics? NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237. This page (NASDAQ:NEO) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeoGenomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.